Genotech Corporation (XKON:066830)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,095.00
-4.00 (-0.36%)
At close: Oct 2, 2025

Genotech Statistics

Total Valuation

Genotech has a market cap or net worth of KRW 6.13 billion.

Market Cap6.13B
Enterprise Value n/a

Important Dates

Earnings Date n/a
Ex-Dividend Date n/a

Share Statistics

Genotech has 5.60 million shares outstanding.

Current Share Class 5.60M
Shares Outstanding 5.60M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 48.66%
Owned by Institutions (%) n/a
Float 2.52M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.84
PB Ratio 1.28
P/TBV Ratio 1.29
P/FCF Ratio 48.91
P/OCF Ratio 16.24
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 1.85.

Current Ratio 0.99
Quick Ratio 0.49
Debt / Equity 1.85
Debt / EBITDA n/a
Debt / FCF 70.91
Interest Coverage -2.64

Financial Efficiency

Return on equity (ROE) is -25.60% and return on invested capital (ROIC) is -4.56%.

Return on Equity (ROE) -25.60%
Return on Assets (ROA) -4.12%
Return on Invested Capital (ROIC) -4.56%
Return on Capital Employed (ROCE) -9.99%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover 0.47
Inventory Turnover 2.13

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -18.28% in the last 52 weeks. The beta is 0.31, so Genotech's price volatility has been lower than the market average.

Beta (5Y) 0.31
52-Week Price Change -18.28%
50-Day Moving Average 1,173.52
200-Day Moving Average 1,348.22
Relative Strength Index (RSI) 45.22
Average Volume (20 Days) 45

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Genotech had revenue of KRW 7.28 billion and -1.32 billion in losses. Loss per share was -280.00.

Revenue7.28B
Gross Profit 962.09M
Operating Income -1.01B
Pretax Income -1.32B
Net Income -1.32B
EBITDA -347.19M
EBIT -1.01B
Loss Per Share -280.00
Full Income Statement

Balance Sheet

The company has 1.21 billion in cash and 8.89 billion in debt, giving a net cash position of -7.68 billion or -1,371.07 per share.

Cash & Cash Equivalents 1.21B
Total Debt 8.89B
Net Cash -7.68B
Net Cash Per Share -1,371.07
Equity (Book Value) 4.80B
Book Value Per Share 1,017.52
Working Capital -55.69M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 377.41 million and capital expenditures -252.05 million, giving a free cash flow of 125.36 million.

Operating Cash Flow 377.41M
Capital Expenditures -252.05M
Free Cash Flow 125.36M
FCF Per Share 22.39
Full Cash Flow Statement

Margins

Gross margin is 13.21%, with operating and profit margins of -13.90% and -18.14%.

Gross Margin 13.21%
Operating Margin -13.90%
Pretax Margin -18.14%
Profit Margin -18.14%
EBITDA Margin -4.77%
EBIT Margin -13.90%
FCF Margin 1.72%

Dividends & Yields

Genotech does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.92%
Shareholder Yield n/a
Earnings Yield -21.55%
FCF Yield 2.04%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Genotech has an Altman Z-Score of -0.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.11
Piotroski F-Score 3